# Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form

> **NCT04037748** · PHASE1 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 72 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Puran T4®
- **DRUG:** Eutirox®

## Key facts

- **NCT ID:** NCT04037748
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-25
- **Primary completion:** 2019-09-11
- **Final completion:** 2019-09-11
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04037748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04037748, "Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04037748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*